Validation of Probiotics as a Microbiome-targeted intervention for Pelvic Inflammatory Disease

Probiotics offer a promising microbiome-targeted intervention (BTI) for managing pelvic inflammatory disease (ID). By restoring beneficial Lactobacillus species and reducing inflammation, they directly counteract the microbial imbalances and immune dysregulation characteristic of ID. This article explores the therapeutic mechanisms of probiotics, their clinical validation, and how they reinforce the accuracy of ID’s microbiome signature as both a diagnostic and therapeutic tool.